Disease-related variables effect on depression and anxiety level in Parkinson’s patients
Objective: To evaluate correlations of depression and anxiety levels with motor symptoms, non-motor symptoms and pharmacological factors in Parkinson's disease (PD). Background: Depression and anxiety…Human-derived α-synuclein antibody BIIB054 binds pathologic forms of α-synuclein and attenuates transmission of α-synuclein in vitro and in vivo
Objective: To identify and characterize a human antibody against α-synuclein (α-syn) for the clinical development of an immunotherapy for Parkinson's disease (PD). Background: α-syn plays…Novel small molecules targeting alpha-synuclein aggregation for the treatment of Parkinson’s disease
Objective: To develop novel, small molecular weight compounds, that can interfere with the aggregation process of alpha-synuclein (aSyn), as disease modifying agents. Background: The aggregation…Critical path for Parkinson’s, I: Data sharing and regulatory science in catalyzing innovation for Parkinson’s disease
Objective: This presentation highlights a new precompetitive consortium based strategy for the successful development of regulatory-endorsed biomarkers and quantitative drug development platforms targeted at the…The Parkinson progression marker initiative (PPMI) – Developing a comprehensive longitudinal biomarker dataset
Objective: The goal of the Parkinson Progression Marker Initiative (PPMI) is to identify clinical, imaging and biospecimen biomarkers of PD progression to provide tools for…Multi-modal recruitment strategy leads to expeditious enrollment in STEADY-PD III
Objective: To review a successful multi-modal recruitment strategy in a clinical trial of early untreated PD patients. Background: STEADY-PD III is a multicenter NINDS funded…
- « Previous Page
- 1
- …
- 14
- 15
- 16